Niazimicin is primarily used in research settings for its potential antimicrobial and antitumor properties. It has shown activity against certain Gram-positive bacteria, making it a candidate for studying novel antibiotic development. In oncology research, niazimicin demonstrates inhibitory effects on specific tumor cell lines by interfering with protein synthesis or cellular proliferation pathways. Its mechanism involves binding to bacterial or mitochondrial ribosomes, which disrupts translation processes in susceptible cells. Due to its structural similarity to other thiopeptide antibiotics, it is also investigated for use in overcoming multidrug resistance in cancer therapy. However, its application remains largely experimental, with ongoing studies to evaluate stability, delivery methods, and selective toxicity.